Clinical Trials Browser

Interventional × Carcinoma, Hepatocellular × IRX 2 × Clear all

NCT03655002 2025-06-17

IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer

Phase 1 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular